Uniqure B.V. (QURE) 26.15 $QURE
Is Legalized Marijuana or Gene Therapy the Better Emerging Industry?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:59AM CDT
The ability to spot powerful new technologies or industries early on can result in eye-popping returns for investors. The brave few that initially recognized the potential of Tesla Motors ' electric car, for example, have been richly rewarded over...
BLUE: 136.49 (+1.22), TSLA: 219.44 (+10.03), QURE: 26.15 (-1.44), GWPH: 113.04 (-0.05), CLDN: 13.59 (-2.77)
Next Week In Biotech: Amgen, AbbVie, Biogen Earnings, UniQure CHMP, AAN Meeting
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
ABT: 48.35 (+1.23), BIIB: 423.57 (+1.46), NEO: 4.84 (-0.03), SGMO: 14.37 (-0.03), IMGN: 9.96 (+0.01), AMGN: 169.10 (+0.64), ILMN: 190.04 (-9.27), SVA: 5.06 (+0.10), BCLI: 4.29 (-0.09), ISRG: 516.93 (-29.80), BABY: 41.64 (+1.71), QURE: 26.15 (-1.44), NURO: 1.32 (-0.02), ABAX: 63.25 (-0.09), GWPH: 113.04 (-0.05), ALXN: 188.19 (+1.41), ABBV: 64.52 (+0.91), AMAG: 57.68 (+0.47), CAT: 84.87 (+0.95), MAA: 76.57 (+1.00), NVS: 103.45 (-0.62)
uniQure Announces Closing of Follow-on Public Offering
GlobeNewswire - Wed Apr 15, 12:00PM CDT
uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the closing of its previously announced follow-on public offering of 3,000,000 ordinary shares at an offering price of $29.50 per ordinary share. In addition, uniQure has granted the underwriters a 30-day option to purchase up to an additional 450,000 ordinary shares from uniQure at the offering price, less underwriting discounts.
QURE: 26.15 (-1.44)
2 Speculative Biotechs That Could Be Well Worth the Risk
George Budwell, The Motley Fool - Motley Fool - Tue Apr 14, 5:59AM CDT
Biotech stocks can produce stunning returns in short order, especially clinical-stage companies working on game-changing drugs or medical devices. These stocks are some of the riskier types of assets, though, frequently plummeting on negative...
QURE: 26.15 (-1.44), PFE: 34.93 (+0.04), CLDN: 13.59 (-2.77), BMY: 66.60 (-0.21), EIDO: 27.75 (+0.22), EXEL: 3.12 (+0.05)
Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 10, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
SBSA: 5.74 (-0.13), LABL: 66.04 (+0.42), QURE: 26.15 (-1.44), MITL: 9.56 (+0.24), DGLY: 13.13 (+0.08), OCUL: 25.90 (-0.05)
Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 423.57 (+1.46), SPHS: 0.82 (+0.01), ADMS: 17.62 (-0.21), TKMR: 18.38 (-0.14), CBYL: 7.02 (-0.38), HPTX: 45.96 (-0.18), QURE: 26.15 (-1.44), SHPG: 253.58 (+3.70), SRPT: 13.52 (+0.04), HZNP: 30.96 (+0.10), GALE: 1.39 (unch), JUNO: 55.72 (-0.68), ABBV: 64.52 (+0.91), CBMG: 32.14 (+2.21), ARNA: 4.47 (+0.01), EXEL: 3.12 (+0.05), ADXS: 22.18 (+0.10), PTLA: 38.48 (-0.47), BMY: 66.60 (-0.21), OCUL: 25.90 (-0.05), NVO: 56.37 (-0.17), DVA: 83.22 (+0.10), HALO: 16.03 (+0.15), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), ALXN: 188.19 (+1.41), NVS: 103.45 (-0.62)
uniQure prices follow-on offering
Seeking Alpha - at Seeking Alpha - Fri Apr 10, 6:07AM CDT
QURE: 26.15 (-1.44)
uniQure Announces Pricing of Follow-on Public Offering
GlobeNewswire - Thu Apr 09, 7:00PM CDT
uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the pricing of its follow-on public offering of 3,000,000 ordinary shares at price to the public of $29.50 per ordinary share. After deducting the underwriting discounts and other estimated offering expenses payable by uniQure, the net proceeds of the follow-on public offering are expected to be approximately $82.4 million (EUR76.5 million). In addition, uniQure has granted the underwriters a 30-day option to purchase up to an additional 450,000 ordinary shares from uniQure at the public offering price, less underwriting discounts. The offering is expected to close on or about April 15, 2015.
QURE: 26.15 (-1.44)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 09, 11:45AM CDT
NPD: 2.87 (+0.25), JRJC: 5.63 (+0.09), MY: 3.13 (+0.02), TRIV: 8.38 (-0.14), DRAM: 2.25 (-0.07), HGSH: 3.10 (-0.06), NYMX: 1.32 (-0.08), NVGN: 7.40 (-0.30), VLTC: 15.14 (-1.04), ORPN: 6.37 (-0.04), CALI: 1.38 (+0.01), QURE: 26.15 (-1.44), CERE: 1.76 (-0.16), FONR: 11.72 (+0.08), STAA: 9.01 (unch), PIR: 12.99 (+0.09), ICLD: 1.66 (-0.06), PGN: 1.82 (+0.06), ZNGA: 2.51 (+0.02), KONE: 4.78 (-0.29)
Uniqure: Leveraging A €3M Acquisition Into A Nearly $300M Shareholder Gain
Mark Biwojno - Seeking Alpha - Thu Apr 09, 9:35AM CDT
UniQure (NASDAQ: QURE ) is an Amsterdam based pioneer in gene therapy. It debuted on the NASDAQ in February of 2014. It is indeed unique as its name suggests because it is the first company in history to receive regulatory approval for a gene therapy...
QURE: 26.15 (-1.44), BMY: 66.60 (-0.21)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Apr 09, 8:11AM CDT
MEMP: 16.95 (-0.16), CRMD: 8.86 (-0.28), INO: 10.39 (-0.09), AMCN: 4.43 (+0.44), QURE: 26.15 (-1.44), ALTR: 42.78 (-0.46), BIOS: 5.23 (+0.04), NVGN: 7.40 (-0.30), ZNGA: 2.51 (+0.02), DGLY: 13.13 (+0.08), INFN: 19.79 (-0.43), EXEL: 3.12 (+0.05)
Rapporteur concludes uniQure's Glybera lacks efficacy; additional post-approval studies may be required
Seeking Alpha - at Seeking Alpha - Thu Apr 09, 6:37AM CDT
QURE: 26.15 (-1.44)
uniQure initiates follow-on equity offering
Seeking Alpha - at Seeking Alpha - Tue Apr 07, 5:35PM CDT
QURE: 26.15 (-1.44)
Nasdaq stocks posting largest volume increases
AP - Tue Apr 07, 5:15PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
JASN: 7.48 (-0.14), INFA: 47.92 (-0.03), TFSC: 9.70 (+0.09), QURE: 26.15 (-1.44), CERU: 5.99 (-0.20), SYRX: 2.09 (-0.05), NECB: 7.78 (-0.02), ESMC: 1.36 (-0.01), VLTC: 15.14 (-1.04), CBMG: 32.14 (+2.21), HCBK: 9.45 (+0.08), OCUL: 25.90 (-0.05)
uniQure Announces Launch of Follow-on Public Offering
GlobeNewswire - Tue Apr 07, 3:29PM CDT
uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that it has commenced a follow-on public offering of 3,000,000 of its ordinary shares. All ordinary shares to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to an additional 450,000 ordinary shares. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
QURE: 26.15 (-1.44)
Company News for April 07, 2015 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Apr 07, 9:10AM CDT
Companies in the News are: VTR,HCBK,MTB,QURE,BMY
QURE: 26.15 (-1.44), MTB: 120.50 (+1.01), BMY: 66.60 (-0.21), HCBK: 9.45 (+0.08), VTR: 72.71 (-0.08)
Bristol-Myers, UniQure partner
at Investor's Business Daily - Mon Apr 06, 5:41PM CDT
The Big Pharma firm announced it had acquired an initial equity stake in UniQure (QURE) as part of a partnership on gene therapies for heart disease. Bristol-Myers Squibb (BMY) is paying $33.83 per share for the stake, above Thu.'s closing price of...
QURE: 26.15 (-1.44), BMY: 66.60 (-0.21)
Is Legalized Marijuana or Gene Therapy the Better Emerging Industry?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:59AM CDT
The ability to spot powerful new technologies or industries early on can result in eye-popping returns for investors. The brave few that initially recognized the potential of Tesla Motors ' electric car, for example, have been richly rewarded over...
BLUE: 136.49 (+1.22), TSLA: 219.44 (+10.03), QURE: 26.15 (-1.44), GWPH: 113.04 (-0.05), CLDN: 13.59 (-2.77)
Next Week In Biotech: Amgen, AbbVie, Biogen Earnings, UniQure CHMP, AAN Meeting
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
ABT: 48.35 (+1.23), BIIB: 423.57 (+1.46), NEO: 4.84 (-0.03), SGMO: 14.37 (-0.03), IMGN: 9.96 (+0.01), AMGN: 169.10 (+0.64), ILMN: 190.04 (-9.27), SVA: 5.06 (+0.10), BCLI: 4.29 (-0.09), ISRG: 516.93 (-29.80), BABY: 41.64 (+1.71), QURE: 26.15 (-1.44), NURO: 1.32 (-0.02), ABAX: 63.25 (-0.09), GWPH: 113.04 (-0.05), ALXN: 188.19 (+1.41), ABBV: 64.52 (+0.91), AMAG: 57.68 (+0.47), CAT: 84.87 (+0.95), MAA: 76.57 (+1.00), NVS: 103.45 (-0.62)
uniQure Announces Closing of Follow-on Public Offering
GlobeNewswire - Wed Apr 15, 12:00PM CDT
uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the closing of its previously announced follow-on public offering of 3,000,000 ordinary shares at an offering price of $29.50 per ordinary share. In addition, uniQure has granted the underwriters a 30-day option to purchase up to an additional 450,000 ordinary shares from uniQure at the offering price, less underwriting discounts.
QURE: 26.15 (-1.44)
2 Speculative Biotechs That Could Be Well Worth the Risk
George Budwell, The Motley Fool - Motley Fool - Tue Apr 14, 5:59AM CDT
Biotech stocks can produce stunning returns in short order, especially clinical-stage companies working on game-changing drugs or medical devices. These stocks are some of the riskier types of assets, though, frequently plummeting on negative...
QURE: 26.15 (-1.44), PFE: 34.93 (+0.04), CLDN: 13.59 (-2.77), BMY: 66.60 (-0.21), EIDO: 27.75 (+0.22), EXEL: 3.12 (+0.05)
Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 10, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
SBSA: 5.74 (-0.13), LABL: 66.04 (+0.42), QURE: 26.15 (-1.44), MITL: 9.56 (+0.24), DGLY: 13.13 (+0.08), OCUL: 25.90 (-0.05)
Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 423.57 (+1.46), SPHS: 0.82 (+0.01), ADMS: 17.62 (-0.21), TKMR: 18.38 (-0.14), CBYL: 7.02 (-0.38), HPTX: 45.96 (-0.18), QURE: 26.15 (-1.44), SHPG: 253.58 (+3.70), SRPT: 13.52 (+0.04), HZNP: 30.96 (+0.10), GALE: 1.39 (unch), JUNO: 55.72 (-0.68), ABBV: 64.52 (+0.91), CBMG: 32.14 (+2.21), ARNA: 4.47 (+0.01), EXEL: 3.12 (+0.05), ADXS: 22.18 (+0.10), PTLA: 38.48 (-0.47), BMY: 66.60 (-0.21), OCUL: 25.90 (-0.05), NVO: 56.37 (-0.17), DVA: 83.22 (+0.10), HALO: 16.03 (+0.15), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), ALXN: 188.19 (+1.41), NVS: 103.45 (-0.62)
uniQure prices follow-on offering
Seeking Alpha - at Seeking Alpha - Fri Apr 10, 6:07AM CDT
QURE: 26.15 (-1.44)
uniQure Announces Pricing of Follow-on Public Offering
GlobeNewswire - Thu Apr 09, 7:00PM CDT
uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the pricing of its follow-on public offering of 3,000,000 ordinary shares at price to the public of $29.50 per ordinary share. After deducting the underwriting discounts and other estimated offering expenses payable by uniQure, the net proceeds of the follow-on public offering are expected to be approximately $82.4 million (EUR76.5 million). In addition, uniQure has granted the underwriters a 30-day option to purchase up to an additional 450,000 ordinary shares from uniQure at the public offering price, less underwriting discounts. The offering is expected to close on or about April 15, 2015.
QURE: 26.15 (-1.44)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 09, 11:45AM CDT
NPD: 2.87 (+0.25), JRJC: 5.63 (+0.09), MY: 3.13 (+0.02), TRIV: 8.38 (-0.14), DRAM: 2.25 (-0.07), HGSH: 3.10 (-0.06), NYMX: 1.32 (-0.08), NVGN: 7.40 (-0.30), VLTC: 15.14 (-1.04), ORPN: 6.37 (-0.04), CALI: 1.38 (+0.01), QURE: 26.15 (-1.44), CERE: 1.76 (-0.16), FONR: 11.72 (+0.08), STAA: 9.01 (unch), PIR: 12.99 (+0.09), ICLD: 1.66 (-0.06), PGN: 1.82 (+0.06), ZNGA: 2.51 (+0.02), KONE: 4.78 (-0.29)
Uniqure: Leveraging A €3M Acquisition Into A Nearly $300M Shareholder Gain
Mark Biwojno - Seeking Alpha - Thu Apr 09, 9:35AM CDT
UniQure (NASDAQ: QURE ) is an Amsterdam based pioneer in gene therapy. It debuted on the NASDAQ in February of 2014. It is indeed unique as its name suggests because it is the first company in history to receive regulatory approval for a gene therapy...
QURE: 26.15 (-1.44), BMY: 66.60 (-0.21)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Apr 09, 8:11AM CDT
MEMP: 16.95 (-0.16), CRMD: 8.86 (-0.28), INO: 10.39 (-0.09), AMCN: 4.43 (+0.44), QURE: 26.15 (-1.44), ALTR: 42.78 (-0.46), BIOS: 5.23 (+0.04), NVGN: 7.40 (-0.30), ZNGA: 2.51 (+0.02), DGLY: 13.13 (+0.08), INFN: 19.79 (-0.43), EXEL: 3.12 (+0.05)
Rapporteur concludes uniQure's Glybera lacks efficacy; additional post-approval studies may be required
Seeking Alpha - at Seeking Alpha - Thu Apr 09, 6:37AM CDT
QURE: 26.15 (-1.44)
uniQure initiates follow-on equity offering
Seeking Alpha - at Seeking Alpha - Tue Apr 07, 5:35PM CDT
QURE: 26.15 (-1.44)
Nasdaq stocks posting largest volume increases
AP - Tue Apr 07, 5:15PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
JASN: 7.48 (-0.14), INFA: 47.92 (-0.03), TFSC: 9.70 (+0.09), QURE: 26.15 (-1.44), CERU: 5.99 (-0.20), SYRX: 2.09 (-0.05), NECB: 7.78 (-0.02), ESMC: 1.36 (-0.01), VLTC: 15.14 (-1.04), CBMG: 32.14 (+2.21), HCBK: 9.45 (+0.08), OCUL: 25.90 (-0.05)
uniQure Announces Launch of Follow-on Public Offering
GlobeNewswire - Tue Apr 07, 3:29PM CDT
uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that it has commenced a follow-on public offering of 3,000,000 of its ordinary shares. All ordinary shares to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to an additional 450,000 ordinary shares. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
QURE: 26.15 (-1.44)
Company News for April 07, 2015 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Apr 07, 9:10AM CDT
Companies in the News are: VTR,HCBK,MTB,QURE,BMY
QURE: 26.15 (-1.44), MTB: 120.50 (+1.01), BMY: 66.60 (-0.21), HCBK: 9.45 (+0.08), VTR: 72.71 (-0.08)
Bristol-Myers, UniQure partner
at Investor's Business Daily - Mon Apr 06, 5:41PM CDT
The Big Pharma firm announced it had acquired an initial equity stake in UniQure (QURE) as part of a partnership on gene therapies for heart disease. Bristol-Myers Squibb (BMY) is paying $33.83 per share for the stake, above Thu.'s closing price of...
QURE: 26.15 (-1.44), BMY: 66.60 (-0.21)
